Live Analyst Rating Changes 2091 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Maughan
CS
William Maughan
Clear Street
Wall Street Analyst
★★★★★
#196
on 13Foresight · ranked by our own returns
35%
Success Rate
-11.7%
Average Return
9 of 26 calls profitable · +0.3% vs benchmark
📈 Across the calls we could measure, roughly 35% of William Maughan's ratings turned a profit when each position was held for 1 year — averaging -11.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

58 Buy 5 Hold 0 Sell
William's Stock Coverage 26 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KRYS
Krystal Biotech
 May 04, 2026 BUY Strong Buy
-27.8% avg upside
19 analysts
$311.00
9.52% Downside
 +21.3%
SMMT
Summit Therapeutics
 May 01, 2026 BUY Strong Buy
+107.5% avg upside
27 analysts
$31.00
117.03% Upside
 -13.9%
WVE
Wave Life Sciences
 Apr 28, 2026 BUY Strong Buy
+259.3% avg upside
28 analysts
$36.00
483.37% Upside
 -18.1%
ANNX
Annexon Biosciences
 Mar 30, 2026 BUY Strong Buy
+176.7% avg upside
13 analysts
$17.00
237.32% Upside
 -1.2%
BEAM
Beam Therapeutics
 Mar 25, 2026 BUY Strong Buy
+46.3% avg upside
25 analysts
$37.00
4.13% Upside
 +47.7%
CLLS
Cellectis SA
 Mar 20, 2026 BUY Strong Buy
+603.6% avg upside
16 analysts
$9.00
219.06% Upside
 +4.8%
MOLN
Molecular Partners
 Mar 13, 2026 BUY Strong Buy
+152.6% avg upside
7 analysts
$8.00
102.60% Upside
 -0.5%
IPSC
Century Therapeutics
 Mar 13, 2026 BUY Strong Buy
+131.8% avg upside
11 analysts
$6.60
186.98% Upside
 -3.9%
KRRO
Korro Bio
 Mar 13, 2026 BUY Strong Buy
+99.1% avg upside
19 analysts
$18.00
29.50% Upside
 -13.7%
BNTX
BioNTech SE
 Mar 11, 2026 BUY Strong Buy
+51.1% avg upside
26 analysts
$167.00
85.15% Upside
 +0.1%
EDIT
Editas Medicine
 Mar 10, 2026 BUY Buy
+392.7% avg upside
33 analysts
$4.60
64.35% Upside
 +0.2%
DNTH
Dianthus Therapeutics
 Mar 10, 2026 BUY Strong Buy
+3.4% avg upside
29 analysts
$130.00
48.76% Upside
 -5.1%
CRBU
Caribou Biosciences
 Mar 06, 2026 BUY Strong Buy
+579.9% avg upside
12 analysts
$13.00
692.73% Upside
 +17.6%
RGNX
RegenXBio
 Mar 06, 2026 BUY Strong Buy
+341.8% avg upside
22 analysts
$45.00
396.18% Upside
 -33.9%
OCUL
Ocular Therapeutix
 Mar 02, 2026 BUY Strong Buy
+149.9% avg upside
21 analysts
$28.00
180.87% Upside
 -9.2%
DCTH
Delcath Systems
 Feb 26, 2026 BUY Strong Buy
+84.9% avg upside
11 analysts
$27.00
134.68% Upside
 +27.9%
CRSP
Crispr Therapeutics AG
 Nov 11, 2025 HOLD Buy
+38.2% avg upside
41 analysts
$50.00
8.08% Downside
 -2.3%
IMCR
Immunocore Holdings
 May 23, 2024 HOLD Strong Buy
+121.4% avg upside
22 analysts
$67.00
128.19% Upside
 -35.1%
OLMA
Olema Pharmaceuticals
 May 15, 2024 BUY Strong Buy
+288.8% avg upside
16 analysts
$24.00
139.94% Upside
 -52.4%
XNCR
Xencor
 May 09, 2024 BUY Strong Buy
+144.9% avg upside
27 analysts
$38.00
171.22% Upside
 -64.6%
NKTX
Nkarta
 May 09, 2024 BUY Strong Buy
+561.5% avg upside
15 analysts
$15.00
437.59% Upside
 -69.4%
FATE
Fate Therapeutics
 May 09, 2024 BUY Buy
+465.3% avg upside
31 analysts
$9.00
318.63% Upside
 -73.3%
MRNA
Moderna
 May 03, 2024 HOLD Hold
+15.8% avg upside
38 analysts
$106.00
78.62% Upside
 -77.9%
BCYC
Bicycle Therapeutics
 Feb 20, 2024 BUY Strong Buy
+507.9% avg upside
20 analysts
$60.00
1407.60% Upside
 -47.1%
NGNE
Neurogene
 Nov 15, 2022 HOLD Buy
+53.6% avg upside
23 analysts
$5.00
84.50% Downside
 +62.4%
BIIB
Biogen
 Sep 05, 2022 BUY Buy
+23.7% avg upside
51 analysts
 — +36.8%
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
William Maughan — Frequently Asked Questions
How accurate are William Maughan's stock ratings?
Based on the calls 13Foresight could measure, about 35% of William's ratings were profitable over a one-year hold, with an average return of -11.6% per rating, or +0.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is William ranked on 13Foresight?
William Maughan is currently ranked #196 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on KRYS, SMMT, WVE, ANNX, BEAM, CLLS, MOLN, IPSC, KRRO, BNTX, EDIT, DNTH and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.